Drug Profile
Ladostigil - Avraham Pharmaceuticals
Alternative Names: Ladostigil hemitartrate; Ladostigil tartrate; TV-3326Latest Information Update: 03 Aug 2022
Price :
$50
*
At a glance
- Originator Hebrew University of Jerusalem
- Developer Avraham Pharmaceuticals; Teva Pharmaceutical Industries
- Class Antidementias; Carbamates; Indans; Neuroprotectants; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; Monoamine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Mild cognitive impairment
- Discontinued Alzheimer's disease
Most Recent Events
- 09 Jul 2019 Phase II development is ongoing for Mild cognitive impairment in Austria, Germany and Israel (Avraham Pharmaceuticals website - July 2019)
- 09 Jul 2019 Avraham Pharmaceuticals has patent protection for ladostigil in USA and Australia (Avraham Pharmaceuticals website - July 2019)
- 26 Aug 2015 Phase-II development for Mild cognitive impairment is ongoing in Austria, Germany and Israel